BMS and cancer centre settle patent exploitation clash
Feud concerned the ownership of six immunotherapy patents | Cancer centre claimed that it was unfairly deprived of royalties.
Scientist accuses Illumina of long-running trade secrets plot
Dispute stems from the theft of a data set of ZipCode sequences used in genetic testing | Plaintiff holds that pharma companies conspired against him | Cornell University claimed Thermo Fisher had misled it into settling a lawsuit in 2017.
AstraZeneca prevails in GSK royalties row at UK High Court
Feud involved a blockbuster cancer drug belonging to a family of PARP inhibitors | GSK unit failed to persuade the court of the merits of its ‘certain uses’ argument.
Pfizer faces infringement suit over COVID-19 vaccine
Arbutus and Genevant claims Pfizer/BioNTech vaccine uses patented technology | Claim follows last year’s lawsuit against Moderna.
Abbvie seeks to block copycat of endometriosis drug
Lawsuit is second to be filed in Delaware over Abbvie’s Orilissa treatment | Abbive says Teva’s ANDA infringes patent granted in January.
GSK signs licence deals with three generics firms to make HIV preventative for low income countries
The three companies will make low-cost versions of HIV PrEP drug | Generics will be available to consumers in 90 low- and middle-income countries.
New York judge awards $33m to Abbott in diabetes test strip dispute
H&H Wholesale Services found to have committed ‘fraud on the court’ | Final amount includes attorneys’ fees and costs.
Notable IP partner joins Lathrop GPM
Recruit from DLA Piper brings two decades of patent and technical experience in life sciences, biotechnology, and healthcare industries.
EPO Enlarged Board of Appeal issues G 2/21 decision
Board provides guidance on evidence submitted after patent filing date | Eagerly awaited decision confirms what’s needed to prove a certain effect.
US refuses to compel lower prices for Pfizer and Astellas cancer drug
NIH rejects petition to use “march-in” rights to allow cheaper competition | Xtandi is “widely available” to public, federal agency says.
